tiprankstipranks
Trending News
More News >
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Advertisement

X4 Pharmaceuticals (XFOR) Stock Statistics & Valuation Metrics

Compare
1,081 Followers

Total Valuation

X4 Pharmaceuticals has a market cap or net worth of $102.82M. The enterprise value is $29.16M.
Market Cap$102.82M
Enterprise Value$29.16M

Share Statistics

X4 Pharmaceuticals has 22,449,133 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,449,133
Owned by Insiders62.52%
Owned by Institutions8.33%

Financial Efficiency

X4 Pharmaceuticals’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -31.97%.
Return on Equity (ROE)-1.69
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-31.97%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee17.88K
Profits Per Employee-261.89K
Employee Count143
Asset Turnover0.02
Inventory Turnover0.28

Valuation Ratios

The current PE Ratio of X4 Pharmaceuticals is 0.7. X4 Pharmaceuticals’s PEG ratio is ―.
PE Ratio0.7
PS Ratio
PB Ratio
Price to Fair Value6.66
Price to FCF
Price to Operating Cash Flow-0.21
PEG Ratio

Income Statement

In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -5.70.
Revenue2.56M
Gross Profit1.76M
Operating Income-36.40M
Pretax Income-37.14M
Net Income-37.45M
EBITDA-27.58M
Earnings Per Share (EPS)-5.70

Cash Flow

In the last 12 months, operating cash flow was -109.30M and capital expenditures -3.13M, giving a free cash flow of -112.43M billion.
Operating Cash Flow-109.30M
Free Cash Flow-112.43M
Free Cash Flow per Share-5.01

Dividends & Yields

X4 Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.61
52-Week Price Change-80.17%
50-Day Moving Average2.19
200-Day Moving Average8.69
Relative Strength Index (RSI)68.08
Average Volume (3m)8.09M

Important Dates

X4 Pharmaceuticals upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

X4 Pharmaceuticals as a current ratio of 3.41, with Debt / Equity ratio of 54.97%
Current Ratio3.41
Quick Ratio3.33
Debt to Market Cap0.51
Net Debt to EBITDA-0.81
Interest Coverage Ratio-4.15

Taxes

In the past 12 months, X4 Pharmaceuticals has paid 310.00K in taxes.
Income Tax310.00K
Effective Tax Rate>-0.01

Enterprise Valuation

X4 Pharmaceuticals EV to EBITDA ratio is -6.16, with an EV/FCF ratio of -1.29.
EV to Sales66.44
EV to EBITDA-6.16
EV to Free Cash Flow-1.29
EV to Operating Cash Flow-1.30

Balance Sheet

X4 Pharmaceuticals has $62.95M in cash and marketable securities with $2.18M in debt, giving a net cash position of -$60.77M billion.
Cash & Marketable Securities$62.95M
Total Debt$2.18M
Net Cash-$60.77M
Net Cash Per Share-$2.71
Tangible Book Value Per Share-$0.78

Margins

Gross margin is 83.00%, with operating margin of -1423.58%, and net profit margin of -1464.61%.
Gross Margin83.00%
Operating Margin-1423.58%
Pretax Margin-1452.48%
Net Profit Margin-1464.61%
EBITDA Margin-1078.45%
EBIT Margin-1109.58%

Analyst Forecast

The average price target for X4 Pharmaceuticals is $6.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.25
Price Target Upside51.70% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast5721.31%
EPS Growth Forecast-671.01%

Scores

Smart Score2
AI Score44
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis